Pay in 4 interest-free payments of $5.58 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Fleur's concept addresses the limitations of current therapies through a biomimetic strategy that leverages the body's natural GLP-1 production mechanisms: Utilize a probiotic oral delivery system to populate the gut microbiome long-term with natural (short-lasting) GLP-1 producing bacteria
10.1016/j.fertnstert.2004.02.120
Setting National pharmaceutical sales and Pharmaceutical Benefits Scheme (PBS) dispensing claims for GLP-1 RA listed for type 2 diabetes (T2D), May 2020-April 2025
Potentially Higher Long-Term Costs From a fiscal responsibility perspective, the growth of these programs (from $886 million in 2019 to nearly $2.7 billion in 2025) deserves scrutiny
US$ 21.81
US$ 28.10
US$ 28.38
US$ 20.22
US$ 26.65
US$ 27.51
US$ 20.11
US$ 22.63
